This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.
IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y
by Zacks Equity Research
The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.
CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.
Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.
Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.
Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.
Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid
by Zacks Equity Research
We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.
AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Align Technology (ALGN) Earnings Beat in Q4, Margins Rise
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.
Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.
PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.
DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add STERIS (STE) to Portfolio Now
by Zacks Equity Research
Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.
NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Steris (STE) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.
Steris (STE) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 4.76% and 2.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in Q1.
Steris (STE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 10.81% and 3.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.